Company Valuation: Cell Source, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Market Cap 1 29.13 63.92 43.22 29.96 17.95 15.26
Change - 119.45% -32.39% -30.67% -40.09% -14.98%
Enterprise Value (EV) 1 31.8 68.58 49.62 37.65 27.22 25.77
Change - 115.68% -27.64% -24.14% -27.68% -5.35%
P/E -5.97x -10.7x -6.58x -4.68x -2.65x -2.49x
PBR -5.19x -8.19x -4.48x -2.43x -1.17x -0.85x
PEG - -7.3x -1.59x 0.7x 0.58x 0.1x
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / EBIT -8.36x -18.9x -12.3x -9.02x -6.51x -6.71x
EV / FCF -39.4x -44.2x -22.8x -28.2x -26.2x -37.4x
FCF Yield -2.54% -2.26% -4.38% -3.55% -3.82% -2.68%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -0.1842 -0.1869 -0.1946 -0.1816 -0.1733 -0.1406
Distribution rate - - - - - -
Net sales - - - - - -
EBITDA - - - - - -
EBIT 1 -3.805 -3.638 -4.019 -4.175 -4.183 -3.84
Net income 1 -4.475 -4.56 -5.472 -5.168 -5.321 -4.513
Net Debt 1 2.67 4.661 6.404 7.682 9.274 10.51
Reference price 2 1.1000 2.0000 1.2805 0.8500 0.4600 0.3500
Nbr of stocks (in thousands) 26,479 31,960 33,752 35,252 39,022 43,602
Announcement Date 3/30/20 4/15/21 4/15/22 8/8/23 6/24/24 4/7/26
1USD in Million2USD
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 36.49M
16.92x6.39x12.26x1.77% 64.14B
30.57x8.11x26.59x0.05% 55.53B
36.68x6.52x19.45x0.88% 53.03B
35.39x3.41x14.74x-.--% 45.99B
49.25x5.68x31.09x-.--% 42.45B
-19.59x189.6x-20.86x-.--% 40.45B
31.7x8.06x20.96x0.41% 32.25B
47.12x8.37x28.08x-.--% 34.47B
27.96x5.9x15.29x-.--% 24.23B
Average 28.44x 26.89x 16.40x 0.34% 39.26B
Weighted average by Cap. 27.96x 25.38x 16.46x 0.45%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Cell Source, Inc.

Historical PBR trend

Valuation ratios - PBR - Cell Source, Inc.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Cell Source, Inc.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Cell Source, Inc.

  1. Stock Market
  2. Stocks
  3. CLCS Stock
  4. Valuation Cell Source, Inc.